基本情報
- CAS
76095-16-4- 標準SMILES
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)O.O=C(O)/C=C\C(=O)O- InChIKey
OYFJQPXVCSSHAI-QFPUQLAESA-N- 分子式
- C24H32N2O9
- 平均分子量
- 492.5 g/mol
- 単同位体質量
- 492.2107806
概要
Enalapril maleate is the maleic acid salt of enalapril. It contains one molecule of maleic acid for each molecule of enalapril. Following oral administration, the ethyl ester group of enalapril is hydrolysed to afford the corresponding carboxylic acid, enalaprilat, an angiotensin-converting enzyme (ACE) inhibitor. Enalapril is thus a prodrug for enalaprilat (which, unlike enalapril, is not absorbed by mouth), and its maleate is used in the treatment of hypertension and heart failure, for reduction of proteinuria and renal disease in patients with nephropathies, and for the prevention of stroke, myocardial infarction, and cardiac death in high-risk patients. It has a role as an EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor, an antihypertensive agent and a prodrug. It contains an enalapril.
名称と識別子
- 優先名称
- Enalapril Maleate
- IUPAC
- (Z)-but-2-enedioic acid;(2S)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]pyrrolidine-2-carboxylic acid
- 現地名
- マレイン酸エナラプリル
- 英語名
- Enalapril maleate
- 分子式
- C24H32N2O9
- 分子量
- 492.52
名称と別名
Enalapril maleate76095-16-4GliotenRenitecVasotecNaprileneXanefHipoartelInnovaceAmpraceEnacardEnapren
名称をさらに表示
エナラプリルマレアートシンベノンバソテクナプロレンエナラートレニメックスパシオールアリカンテレニベースレニテンエナリンプレスイントニス1-[N-[(S)-1-(エトキシカルボニル)-3-フェニルプロピル]-L-アラニル]-L-プロリン·マレイン酸レビンベースエナプレンレノペントマレイン酸エナラプリルラリルドンファルプリルOlivinEnalapril Maleate SaltRenitekRenivace(S)-1-((S)-2-((S)-1-ETHOXY-1-OXO-4-PHENYLBUTAN-2-YLAMINO)PROPANOYL)PYRROLIDINE-2-CARBOXYLIC ACID MALEATEBQLEnvasNuril
RenitenPresEdnytEpanedEpaned KitMK-421CARDIOVETNSC-758143
物性
構造計算による物性
- 極性表面積
- 171 Ų
- 水素結合供与体数
- 4
- 水素結合受容体数
- 10
- 回転可能結合数
- 12
- 重原子数
- 35
- 形式電荷
- 0
- 複雑度
- 637
実験および物理化学的性質
Human Drugs
Breast Feeding; Lactation; Milk, Human; Antihypertensive Agents; Angiotensin-Converting Enzyme Inhibitors; ACE Inhibitors; ACEIs
FDA approved drugs -> Active ingredient
EMA approved medicines: Human medicine
FDA approved drugs -> Active ingredient
Collision Cross Section186.6 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
物理化学的性質
- 融点
- 143 · 143-144,5°C
- 比旋光度
- 25 · D25 -42.2° (c = 1 in methanol)
- 沸点
- 0 °C · 0°C
- 比重(密度)
- 1.27 g/cm³ · 1.27 g/cm³ (liquid)
- 闪点
- 0 °C · 0°C
- 貯蔵温度
- 2 · 2-8°C
- 溶解性
- 50 mg/mL、透明、無色～黄色 · メタノール：～50mg/mL、透明、無色～黄色
- 外見
- 粉
- 酸解離定数(Pka)
- 1 · pKa1 3.0; pKa2 (25°) 5.4
- 色
- ホワイトからオフホワイト
- 水溶解度
- 水、メタノール、エタノールに可溶。
- Merck
- 14 · 14,3567
- BCS Class
- 1 · 1 (LogP), 3 (CLogP)
安全と法規制
GHS分類
GHS Classification
This chemical does not meet GHS hazard criteria for 1% (2 of 202) of reports.
Danger
H302 (19.3%): Harmful if swallowed [Warning Acute toxicity, oral]
P203, P260, P263, P264, P264+P265, P270, P280, P301+P317, P305+P351+P338, P305+P354+P338, P317, P318, P319, P330, P337+P317, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 202 reports by companies from 27 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
危険有害性情報
Regulatory InformationEnalapril maleate: Non hazardous
Hazard Classes and CategoriesAcute Tox. 4 (19.3%)
毒性情報
Drug Induced Liver Injury
Drug Induced Liver Injury Rank (DILIrank 2.0)
Enalapril maleate
vLess-DILI-concern
7
Adverse reactions
DOI:10.1016/j.drudis.2016.02.015
Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
安全データ
- wgk
- 2
- rtecs
- TW3666000
- ridadr
- 3077
- 毒性
- LD50 oral in rat: 2973mg/kg
- hs_code
- 29339900
- risk_code
- 36/37/38-62-63
- hazard_code
- Xi,Xn
- safety_code
化学と産業
薬理情報
FDA Pharmacological Classification
ENALAPRIL MALEATE
Angiotensin-converting Enzyme Inhibitors [MoA]; Decreased Blood Pressure [PE]; Angiotensin Converting Enzyme Inhibitor [EPC]
ENALAPRIL MALEATE ORAL SOLUTION
Angiotensin Converting Enzyme Inhibitor [EPC]; Decreased Blood Pressure [PE]; Angiotensin-converting Enzyme Inhibitors [MoA]
MeSH Pharmacological Classification
A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility.
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS.
応用分野
用途アンジオテンシン変換酵素 （ACE-1）阻害剤です。アンジオテンシン変 換酵素を阻害し、アンジオテンシンⅡ生成抑 制作用を示します。
用途アンジオテンシン変換酵素 （ACE）阻害剤です。アンジオテンシン変換 酵素を阻害し、アンジオテンシンⅡ生成抑制 作用を示します。
用途高血圧の研究。
説明Enalapril maleate is the second angiotensin converting enzyme inhibitor to reach the marketplace. Like captopril, the first entry in this area, enalapril is useful in the treatment of hypertension and congestive heart failure. It has a longer effective half-life than captopril, allowing once or twice-daily dosing, and appears to have a somewhat lower incidence of side effects.
使用Enalapril maleate salt is used as a long-acting ACE inhibitor and antihypertensive, used to study diabetic angiopathy in diabetic rats and inhibition of ACE in hog plasma (I50=1.2nM). ACE inhibitors disturb the enin-angiotensin- aldosterone system. Additional ACE inhibitors include: Enalapril, Enalaprilat dihydrate, Enalaprilat, and Enalapril-d5 Maleate Salt, among others.
関連反応
15 件
化合物ノート
読み込み中…